Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 1998

View Archived Issues

B43-PAP: a promising treatment for Ph+ ALL in development at Hughes Institute

Shire: nine-month 1998 highlights

Novo Nordisk: nine-month 1998 highlights

Ligand: Q3 1998 highlights

Nortran announces positive phase II trial results with RSD-921

OraVax files IND for colitis vaccine

Company Profile: Cetek

GlycoDesign expands phase II cancer trial with GD0039

Cell Genesys broadens GVAX trials program in prostate cancer

Neurocrine Biosciences advances development of NBI-3001

Inex receives patent protection for vital component of TCS delivery system

Transkaryotic Therapies extends agreement with PolyMASC to include second drug candidate

Multiple clinical studies support efficacy and safety of HSR-237 in patients with IBS

International study focuses on riluzole as a new approach to treating PD

New market introductions for raloxifene

SSRI promising in the treatment of children and adolescents with OCD

Unimed receives U.S. patent protection for dronabinol in treatment of dementia

FDA advisory committee meets this week to discuss Celebrex NDA

LTA4 hydrolase inhibitors reported in development at Santen

Antimicrobial and antitumor activity of xenomin compounds described

Shionogi claims new agents for influenza

TAK-778: candidate for development in the treatment of osteoporosis

Banyu reports success in the search for new ACAT inhibitors

Fujisawa discovers V-ATPase inhibitor with potential for treating osteoporosis

Alkermes, Schering-Plough agree to terminate collaboration

Guilford presents two new series of NAALADase inhibitors

Australian team demonstrates safety of diabetes vaccine in patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...